Austria's Intercell AG Expands Alliance With Merck & Co., Inc.; Intercell Receives Upfront Payment US $9.5M and Up To US $76M Milestones
VIENNA, Oct 27 (Reuters) - Austrian biotech firm Intercell (ICEL.VI: Quote, Profile, Research) will provide U.S. drug maker Merck & Co (MRK.N: Quote, Profile, Research) with technology for a vaccine against streptococcus infections, expanding its cooperation with Merck.